The CRI-ENCI Ninth International Cancer Immunotherapy Conference (CICON25): Translating Science Into Survival will take place September 10–12, 2025, in Utrecht, The Netherlands.
CICON25 is co-presented by the Cancer Research Institute (CRI) and the European Network for Cancer Immunotherapy (ENCI). The CICON conference series is a leading global forum for cutting-edge translational immuno-oncology research. Held alternately in the United States and Europe since 2015, this conference will bring together over 1,000 international experts in the field.
CICON25 will present plenary lectures, proffered talks, roundtable discussions, poster sessions, as well as industry exhibits. Additional talks will be selected from submitted abstracts, showcasing the latest advancements in cancer immunotherapy. Poster sessions will offer a platform for in-depth discussions on specific studies, encouraging collaborative exploration and innovation.
For CICON25, the Netherlands was selected by ENCI as the ideal host country. With its strong research and innovation economy, the Netherlands offer the perfect venue to unite scientific leaders, clinicians, and industry partners.
CICON25 will provide an opportunity for institutes and companies to present their technology, services, and company culture. Interested companies are invited to support CICON25 by becoming a sponsor or by booking and industry exhibition space.
For more information, please see the website!
Abstract submission in the following categories is now open through June 1, 2025:
- New Targets and Lead Structures
- Tumor Microenvironment and Immunosuppression
- Computational Immunology
- Cellular Therapies
- Biomarker Strategies
All accepted abstracts are presented as posters. Authors of highly rated abstracts will be invited to give short talk presentations.
To submit your abstract, please go to: https://cancerimmunotherapyconference.org/abstract/